Abstract:Myelin is the lipidic insulating structure enwrapping axons and allowing fast saltatory nerve conduction. In the central nervous system, myelin sheath is the result of the complex packaging of multilamellar extensions of oligodendrocyte (OL) membranes. Before reaching myelinating capabilities, OLs undergo a very precise program of differentiation and maturation that starts from OL precursor cells (OPCs). In the last 20 years, the biology of OPCs and their behavior under pathological conditions have been studied through several experimental models. When co-cultured with neurons, OPCs undergo terminal maturation and produce myelin tracts around axons, allowing to investigate myelination in response to exogenous stimuli in a very simple in vitro system. On the other hand, in vivo models more closely reproducing some of the features of human pathophysiology enabled to assess the consequences of demyelination and the molecular mechanisms of remyelination, and they are often used to validate the effect of pharmacological agents. However, they are very complex, and not suitable for large scale drug discovery screening. Recent advances in cell reprogramming, biophysics and bioengineering have allowed impressive improvements in the methodological approaches to study brain physiology and myelination. Rat and mouse OPCs can be replaced by human OPCs obtained by induced pluripotent stem cells (iPSCs) derived from healthy or diseased individuals, thus offering unprecedented possibilities for personalized disease modeling and treatment. OPCs and neural cells can be also artificially assembled, using 3D-printed culture chambers and biomaterial scaffolds, which allow modeling cell-to-cell interactions in a highly controlled manner. Interestingly, scaffold stiffness can be adopted to reproduce the mechanosensory properties assumed by tissues in physiological or pathological conditions. Moreover, the recent development of iPSC-derived 3D brain cultures, called organoids, has made it possible to study key aspects of embryonic brain development, such as neuronal differentiation, maturation and network formation in temporal dynamics that are inaccessible to traditional in vitro cultures. Despite the huge potential of organoids, their application to myelination studies is still in its infancy. In this review, we shall summarize the novel most relevant experimental approaches and their implications for the identification of remyelinating agents for human diseases such as multiple sclerosis.

Cell‐based experimental strategies for myelin repair in multiple sclerosis

Cell-based remyelinating therapy in inflammatory demyelinating injury of the CNS

Remyelinating Pharmacotherapies in Multiple Sclerosis

Remyelination in multiple sclerosis: cellular mechanisms and novel therapeutic approaches

Mechanisms of Demyelination and Remyelination Strategies for Multiple Sclerosis

New targets and therapeutics for neuroprotection, remyelination and repair in multiple sclerosis

Repair of Myelin Disease: Strategies and Progress in Animal Models

Emerging myelin repair agents in preclinical and early clinical development for the treatment of multiple sclerosis

Remyelination therapies for multiple sclerosis: optimizing translation from animal models into clinical trials

Targeting Oligodendrocyte Dynamics and Remyelination: Emerging Therapies and Personalized Approaches in Multiple Sclerosis Management

Targeting Microglia and Macrophages: A Potential Treatment Strategy for Multiple Sclerosis

Oligodendrocyte progenitor programming and reprogramming: Toward myelin regeneration

Clinical Applications of Myelin Plasticity for Remyelinating Therapies in Multiple Sclerosis

Novel in vitro Experimental Approaches to Study Myelination and Remyelination in the Central Nervous System

Central nervous system regeneration: the roles of glial cells in the potential molecular mechanism underlying remyelination

Remyelination in the CNS: from biology to therapy

The Therapeutic Mechanisms of Mesenchymal Stem Cells in MS—A Review Focusing on Neuroprotective Properties

Strategies for myelin regeneration: lessons learned from development

Nanosystems and exosomes as future approaches in treating multiple sclerosis

The interplay of inflammation and remyelination: rethinking MS treatment with a focus on oligodendrocyte progenitor cells

Multiple sclerosis treatments a review of current biomedical engineering approaches